- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01535222
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery
A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective CABG Surgery
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
This protocol describes a study of the investigational drug MDCO-2010 as a haemostasis modulator in patients undergoing elective Coronary Artery Bypass Graft (CABG) surgery involving a cardiopulmonary bypass (CPB).
Perioperative bleeding is a serious complication that adversely affects the morbidity and mortality of cardiac surgery. To alleviate this complication, prophylactic antifibrinolytic therapies are now widely accepted as a strategy to inhibit excessive fibrinolysis.
MDCO-2010, a synthetic small molecule, is a direct inhibitor of plasmin and plasma kallikrein. Both of these have been implicated with impaired haemostasis. In addition, potent inhibition of coagulation factors Xa, XIa and activated Protein C has been demonstrated. Thus, MDCO-2010 has the potential to mitigate excessive fibrinolysis and thrombin generation during cardiac surgery involving a cardiopulmonary bypass. In particular the latter is supposed to provide additional benefits beyond reducing transfusion requirements.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria
- Men, aged 18 to 80 years or
- Post-menopausal women, aged up to 80 years. Postmenopausal status defined as ≥ 1 year since last menstruation in women with no medical history of hysterectomy or women with a medical history of bilateral oophorectomy
- Planned elective, isolated primary CABG surgery with more than 1 graft, including the use of cardiopulmonary bypass
- Written informed consent prior to any study-related procedure not part of normal medical care
Exclusion Criteria
Patients may not meet any of the following exclusion criteria:
- Planned concomitant surgery including atrial septal defect (ASD) repair, valve replacement, carotid endarterectomy, aortic surgery, any combined procedure or any repeat sternotomy
- Planned Off-pump CABG
- Body weight < 55 kg or > 110 kg
- Planned hypothermia < 28°C
- Major surgical procedures within 30 days of entry
- Placement of drug-eluting stent (DES) within 12 months or of bare-metal stent (BMS) within 6 weeks of entry in a vessel which is not intended to be grafted
- Ejection fraction < 35%
Preoperative coagulation abnormalities
- Platelet count < 100,000/cubic mm, or
- INR > 1.5 or Quick < 40%, or
- activated partial thromboplastin time (aPTT) > 1.5 x upper limit of normal (ULN)
- Preoperative Hb < 11 g/dL for male patients or < 10 g/dL for female patients
- Patient refusal to receive donor blood products if necessary
- Administration of thienopyridines within 5 days prior to surgery Administration of warfarin within 5 days prior to surgery
- Administration of tirofiban or eptifibatide within 24 hours or administration of abciximab within 5 days prior to surgery
- Administration of fondaparinux within 24 hours prior to surgery
- Creatinine clearance (calculated using Cockroft-Gault equation) < 60 mL/min
- Planned intraoperative use of tranexamic acid or of ε-aminocaproic acid
- History of stroke or transient ischemic attack within 3 months prior to entry
- Known heparin-induced thrombocytopenia
- Known history of thrombophilia, eg, deep vein thrombosis (DVT) with pulmonary embolism
- Active liver disease
- Any condition requiring chronic immunosuppressive medication
- Receipt of an investigational drug or device 30 days prior to entry
- Any other condition which, in the opinion of the investigator, would prevent a patient's participation in the study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Cohort 1
3 patients: loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg
|
MDCO-2010 solution for infusion.
Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
Andere Namen:
|
Experimental: Cohort 2
3 pts: loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg
|
MDCO-2010 solution for infusion.
Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
Andere Namen:
|
Experimental: Cohort 3
6 patients: loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg
|
MDCO-2010 solution for infusion.
Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
Andere Namen:
|
Experimental: Cohort 4
6 patients: loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg
|
MDCO-2010 solution for infusion.
Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
Andere Namen:
|
Experimental: Cohort 5
6 patients: loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg
|
MDCO-2010 solution for infusion.
Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
Andere Namen:
|
Placebo-Komparator: Placebo
8 patients: commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion
|
Commercially available NaCl
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Incidence of Adverse Events
Zeitfenster: 7 days (day of surgery to day 7)
|
Number of patients experiencing Adverse Events
|
7 days (day of surgery to day 7)
|
Incidence of Serious Adverse Events
Zeitfenster: 7 days (day of surgery to day 7)
|
Number of patients experiencing Serious Adverse Events
|
7 days (day of surgery to day 7)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Lars Englberger, PD Dr. Med., University Hospital Inselspital, Bern
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- TMC-CU-10-01
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Herz-Lungen-Bypass
-
Nanjing First Hospital, Nanjing Medical UniversityAbgeschlossenHerz-Lungen-Bypass | Koronararterien-Bypass-OperationChina
-
Università Vita-Salute San RaffaeleAbgeschlossenHerzchirugie | Koronararterien-Bypass-Operation | Aortokoronarer BypassKroatien, Italien, China, Malaysia, Russische Föderation, Portugal, Bahrein, Brasilien, Bulgarien, Tschechien, Ägypten, Saudi-Arabien, Serbien
-
EgymedicalpediaAbgeschlossenKoronararterien-Bypass-Operation | Koronare Bypass-StenoseÄgypten
-
Lawson Health Research InstituteMedtronicAbgeschlossenHerz-Lungen-Bypass | Koronararterien-Bypass-OperationKanada
-
Yale UniversityGlenn Memorial FundRekrutierung
-
Assistance Publique - Hôpitaux de ParisGFIAbgeschlossenKoronararterien-BypassFrankreich
-
Henan Institute of Cardiovascular EpidemiologyAktiv, nicht rekrutierendKoronararterien-BypassChina
-
University of VirginiaNational Institute for Biomedical Imaging and Bioengineering (NIBIB)UnbekanntKoronararterien-BypassVereinigte Staaten
-
University of MiamiNational Heart, Lung, and Blood Institute (NHLBI)AbgeschlossenKoronararterien-BypassVereinigte Staaten
-
Imperial College LondonUnbekanntKoronararterien-BypassVereinigtes Königreich
Klinische Studien zur MDCO-2010
-
The Medicines CompanyBeendet
-
Guangdong Hengrui Pharmaceutical Co., LtdAbgeschlossen
-
Assiut UniversityNoch keine RekrutierungRheumatoide Arthritis
-
Pharmazz, Inc.Noch keine Rekrutierung
-
Pharmazz, Inc.Noch keine Rekrutierung
-
Pharmazz, Inc.Abgeschlossen
-
Chang Gung Memorial HospitalAbgeschlossenStumpfe Verletzungen
-
Pharmazz, Inc.AbgeschlossenHypovolämischer SchockIndien
-
Guangdong Hengrui Pharmaceutical Co., LtdRekrutierungPrimäre IgA-NephropathieChina
-
KarmelSonix Ltd.Unbekannt